Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
43 hedge funds and large institutions have $24.3M invested in Biostage, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 19 reducing their positions, and 12 closing their positions.
19% less funds holding
Funds holding: 53 → 43 (-10)
30% less capital invested
Capital invested by funds: $35M → $24.3M (-$10.7M)
63% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 19
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$228K |
| 2 |
6CM
683 Capital Management
New York
|
+$170K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$133K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$54K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARC
Absolute Return Capital
Boston,
Massachusetts
|
-$506K |
| 2 |
Morgan Stanley
New York
|
-$454K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$429K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$287K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$263K |
BSTG Hedge Fund Activity: Q3 2014 in Review
43 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q3 2014, worth a combined $24.3M — down 30% from $35M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of BSTG and 2 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, adding an estimated $228K. The largest seller was Absolute Return Capital, exiting entirely with an estimated $506K sold.
- 43 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q3 2014, down from 53 in Q2 2014.
- Funds reported $24.3M of Biostage, Inc. Common Stock stock for Q3 2014, down 30% quarter-over-quarter.
- 2 funds opened new Biostage, Inc. Common Stock positions in Q3 2014 and 12 closed out, a net change of -10 holders.
- The largest Biostage, Inc. Common Stock buyer in Q3 2014 was Sabby Management, an estimated $228K added.
- The largest Biostage, Inc. Common Stock seller in Q3 2014 was Absolute Return Capital, an estimated $506K sold.
Based on aggregated 13F filings for Q3 2014.